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Abstract
Background: HIV preferentially infects CD4+ T cells, and the functional impairment and numerical decline of CD4+
and CD8+ T cells characterize HIV disease. The numerical decline of CD4+ and CD8+ T cells affects the optimal
ratio between the two cell types necessary for immune regulation. Therefore, this work aimed to define the
genomic basis of HIV interactions with the cellular transcriptome of both CD4+ and CD8+ T cells.
Results: Genome-wide transcriptomes of primary CD4+ and CD8+ T cells from HIV+ patients were analyzed at
different stages of HIV disease using Illumina microarray. For each cell subset, pairwise comparisons were
performed and differentially expressed (DE) genes were identified (fold change >2 and B-statistic >0) followed by
quantitative PCR validation. Gene ontology (GO) analysis of DE genes revealed enriched categories of complement
activation, actin filament, proteasome core and proton-transporting ATPase complex. By gene set enrichment
analysis (GSEA), a network of enriched pathways functionally connected by mitochondria was identified in both
T cell subsets as a transcriptional signature of HIV disease progression. These pathways ranged from metabolism
and energy production (TCA cycle and OXPHOS) to mitochondria meditated cell apoptosis and cell cycle
dysregulation. The most unique and significant feature of our work was that the non-progressing status in HIV+
long-term non-progressors was associated with MAPK, WNT, and AKT pathways contributing to cell survival and
anti-viral responses.
Conclusions: These data offer new comparative insights into HIV disease progression from the aspect of HIV-host
interactions at the transcriptomic level, which will facilitate the understanding of the genetic basis of transcriptomic
interaction of HIV in vivo and how HIV subverts the human gene machinery at the individual cell type level.
Background
HIV preferentially infects CD4+ T cells and the functional
impairment and numerical decline of CD4+ and CD8+
T cells characterize HIV disease. The numerical decline of
CD4+ and CD8+ T cells affects the optimal ratio between
the two cell types necessary for immune regulation. This
ratio can predict the progression or non-progression to
HIV disease [1]. In HIV+ non-progressing individuals,
who control viremia in the absence of antiviral therapy,
polyclonal, persistent, and vigorous HIV-1-specific CD4+
T cell proliferative responses are present, resulting in the
elaboration of interferon and antiviral chemokines [2].
HIV disease progression leads to a wide range of defects
in CD4+ T cell function, such as altered profiles of cyto-
kine production [3], weak or absent HIV-specific CD4+
T cell proliferation [4,5], dysregulation of CD4+ T cell
turnover [6], and impaired production of new cells [7,8].
The cytotoxic and non-cytotoxic antiviral arms of CD8+
T cells are potent in controlling HIV replication [9]. The
non-cytotoxic activity including chemokines, soluble CD8
antiviral factor, urokinase-type plasminogen activator, and
antiviral membrane-bound factor suppresses HIV tran-
scription in an antigen-independent and major histocom-
patibility complex-unrestricted manner [10]. The
induction of memory cytotoxic CD8+ T cells in early HIV
infection, particularly Gag-specific cells, helps control viral
replication and is associated with slower CD4+ T cell
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any medium, provided the original work is properly cited.decline [11]. Host cytolytic effector responses appear to
delay the disease progression [12]. In HIV disease progres-
sion, numerical decline and functional impairment of
CD8+ T cells can be attributed to increased susceptibility
to apoptosis from alterations in the cytokine milieu in
lymphoid tissue, bystander effects from neighboring pro-
ductively infected CD4+ T cells, and toxicity from the
release of HIV-derived gp120 or Tat proteins, in addition
to direct infection [13,14]. Although the direct and indirect
HIV-induced mechanisms leading to CD4+ and CD8+
T cell depletion are known, the genetic basis of these
pathogenic mechanisms are uncertain. To better under-
stand HIV pathogenesis at the genomic level, investigators
have carried out microarray-based studies of HIV infec-
tion, including the use of whole PBMC, cell lines, mono-
cytes, macrophages, T cells, lymphoid and gut tissue [15].
For CD4+ T cells, reports mainly focused on T cell lines
in vitro, except for one study reporting resting CD4+
T cells in viremic versus aviremic HIV+ individuals [16].
The limitation of in vitro studies is that they do not reflect
effects observed in vivo, as HIV induces T cell dysfunction
systemically and affects both the HIV-infected cells and
the majority of bystander cells. Studies on CD8+ T cells
are limited, and include searching for genes responsible
for non-cytotoxic CD8+ T cell activity and comparisons
between individuals with high non-cytotoxic activity and
uninfected controls [17,18]. Recently, the transcriptional
profiling of CD4+ and CD8+ T cells from early infection,
chronic infection, and LTNP patients has been reported
[19]. Interferon responses as a transcriptional signature of
T cells from early and chronically infected patients were
identified, but no pronounced difference between early
and chronically infected patients, between HIV seronega-
tive controls and LTNPs was detected; thus, combined
groups had to be used to facilitate further analysis [19].
Using Illumina Human-6 V2 Expression BeadChips
encompassing all 27,000 human genes (=48,000 gene
transcripts), recently we have successfully identified
coordinated up-regulation of oxidative phosphorylation
(OXPHOS) genes as a transcriptional signature in CD8+
T cells from the viremic patients on HAART and the
possible association between components of MAPK
pathway and LTNP status [20]. Further study suggested
a correlation between HIV load level and CD8+ T cell
transcriptome shift [21], supporting that detection
threshold of viral load could be used as an accurate
grouping criteria in differentiating HIV disease status.
Here, in this study we compared global gene expression
profiles of all 25,000 human genes for both primary
CD4+ and CD8+ T cells from three HIV+ disease
groups along with healthy HIV seronegative controls.
The various HIV+ disease groups included long-term
non-progressors (LTNPs) and viremic patients on
HAART (VIR), as well as aviremic patients on HAART
(below detectable levels, BDL). Using Illumina Human-6
V2 Expression BeadChips, comparative genome-wide
transcriptomic analysis of ex-vivo collected CD4+ and
CD8+ T cells clearly showed evidence for concerted up-
regulation of metabolic pathways during HIV disease
progression, and a clear correlation between transcrip-
tome shift and detectable plasma viremia uniquely for
CD8+ T cells. A novel observation was that HIV non-
progression was associated with enriched MAPK, WNT,
and AKT pathways. Although both CD4+ and CD8+
T cell transcriptomes showed overlaps at the pathway
level, other pathways that segregated these cellular tran-
scriptomes during disease progression were identified,
suggesting that HIV also maintains distinct interaction
with these cell types in vivo. Detection of such tran-
scriptomic signatures for progressive and non-progres-
sive HIV disease may not only facilitate the
understanding of genetic basis of HIV interaction with
variety of blood leukocytes but also lead to the develop-
ment of new biomarkers in predicting disease rates.
Results
Analysis of differentially expressed genes and enriched
gene ontology category
CD4+ and CD8+ T cell-derived total cellular RNA from
14 HIV-infected individuals (4 LTNP, 5 BDL and 5 VIR,
Table 1) and 5 HIV seronegative (NEG) healthy indivi-
duals were hybridized to the Sentrix Human-6 V2
Expression BeadChip (Singapore). After passing quality
assessment, data normalization was performed and a lin-
ear model fit in conjunction with an empirical Bayes sta-
tistics were used to identify candidate DE genes [22,23].
For both CD4+ and CD8+ T cells, pairwise comparisons
from the four study groups (BDL versus NEG, VIR versus
NEG, LTNP versus NEG, BDL versus LTNP, VIR versus
LTNP, BDL versus VIR) were carried out and candidate
DE genes with >2-fold change and B-statistic > 0 were
identified for each comparison. The number of DE genes
identified in each comparison is listed in Table 2 and the
list of DE genes for each comparison between HIV+ dis-
ease groups are provided in Additional File 1.
To identify the important functional categories from
the DE genes, GO Tree was used to identify GO cate-
gories with significantly enriched gene numbers (P <
0.01). For BDL versus VIR and VIR versus LTNP com-
parisons in CD4+ T cells, the GO categories response to
stimuli and extracellular region were significantly
enriched (p <0.01; Figure 1A and 1B). The sub-tree view
under the above categories revealed that both comple-
ment activation with contributing genes C1QB, C1QC,
and SERPING1, and complement component C1q com-
plex with contributing genes C1QA and C1QB were sig-
nificantly enriched. For the VIR and LTNP comparison
in CD8+ T cells, response to stimuli, catalytic activity,
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Further inspection of these enriched categories showed
that at level 7, category cytosol with contributing genes
BAG3, PRF1, UNC119, ARFIP1, PSME2, PSMA5,
PSMB2, PSMB8, and PSMB10, category actin filament
with contributing genes IQGAP1, ACTB, and ACTA2,
category proteasome core complex with contributing
genes PSMA5, PSMB2, PSMB8, and PSMB10, and cate-
gory proton-transporting ATPase complex with contri-
buting genes ATP5J2, ATP6V0E1, and ATP6V1 D were
significantly enriched (Figure 1D).
Validation of differentially expressed genes
To confirm the DE genes from the Illumina microarray,
mRNA expression levels of the selected DE genes from
each paired comparison for both CD4+ and CD8+
T cells were measured by quantitative real-time PCR
(Table 3). DE genes contributing to the enriched GO
categories were randomly selected for real-time PCR
confirmation. For CD8+ T cells, these genes included
BAG3 in category cytosol, ACTA2 in category actin,
PSMB2 and PSMA5 in category proteasome core com-
plex, and ATP6V1 D in category proton-transporting
ATPase complex. For CD4+ T cells, C1QB, C1QC, and
SERPING1 in category complement activation were
selected. DE genes not under any enriched GO cate-
gories were also randomly selected. The mRNA from
the CD4+ and CD8+ T cells of the same patient at the
same time point was used for real-time multiplexed
qPCR analysis. The fold changes were evaluated by real-
time multiplexed qPCR and were well consistent with
the results from differentially expressed genes obtained
by microarray (Table 3).
Gene set enrichment analysis
To further unravel the biological mechanisms differen-
tiating between HIV disease groups, pairwise compari-
sons using GSEA were performed for both CD4+ and
CD8+ T cells from three HIV+ groups (VIR versus
BDL, VIR versus LTNP, and BDL versus LTNP). Rather
than single DE genes, GSEA evaluates microarray data
at the biological pathway level by performing unbiased
global searches for genes that are coordinately regulated
in predefined gene sets [24]. The number of significantly
enriched gene sets (FDR < 0.05/0.1) in each pairwise
comparison is listed in Table 4. The representative plots
of gene set numbers against the FDR value (BDL versus
LTNP and VIR versus LTNP in CD8+ T cells, BDL
Table 1 Patient clinical detail
Patient Group Age Viral load (copies/ml) CD4 counts (cells/μl) CD8 counts (cells/μl)
V1 VIR 46 209 300 566
V2 VIR 41 2530 278 845
V3 VIR 40 5710 324 1169
V4 VIR 43 546,000 94 312
V5 VIR 60 683,000 48 73
B1 BDL 48 < 50 450 288
B2 BDL 63 < 50 480 360
B3 BDL 40 < 50 1065 1065
B4 BDL 62 < 50 776 1692
B5 BDL 59 < 50 251 548
L1 LTNP 59 < 50 630 579
L2 LTNP 51 < 50 714 476
L3 LTNP 79 < 50 920 900
L4 LTNP 33 57 780 900
V1-5: viremic patients on HAART; B1-5: aviremic patients on HAART; L1-4: long-term non-progressors. All the patients and seronegative controls are males.
Plasma viral load was measured using the Quantiplex HIV RNA3.0 (Chiron bDNA) assay with a lower limit of detection of 50 HIV-1 copies/ml (Chiron Diagnostics,
Halstead, United Kingdom).
Table 2 Number of differentially expressed genes in
pairwise comparisons for CD4+ and CD8+ T cells (fold
change > 2 and B-statistic > 0)
Differentially
expressed genes
CD4 CD8 CD4 and CD8
up down up down up down
BDLvsNEG 50 24 206 72 15 3
VIRvsNEG 173 128 477 273 79 48
LTNPvsNEG 5 9 17 6 0 0
BDLvsLTNP 0 3 3 1 0 0
VIRvsLTNP 29 7 118 63 10 2
BDLvsVIR 1 8 5 12 0 1
Up: up-regulation; down: down-regulation; vs: versus; CD4 and CD8: genes
differentially expressed in both CD4+ and CD8+ T cells in the same paired
comparison.
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Page 3 of 21Figure 1 Gene ontology (GO) tree and bar chart for the enriched GO categories. GO categories with at least 2 genes and p < 0.01 are
identified as enriched and colored red in the GOTree. In GOTree, O stands for observed gene number in the category; E for expected gene
number in the category; R for ratio of enrichment for the category; and P for p value calculated from the statistical test given for the categories
with R > 1 to indicate the significance of enrichment. A. GO tree for the differentially expressed genes in CD4+ T cells between the BDL and VIR
groups. B. GO tree for the differentially expressed genes in CD4+ T cells between the VIR and LTNP groups. C. GO tree for the differentially
expressed genes in CD8+ T cells between the VIR and LTNP groups. D. Bar chart of level 7 categories under cellular component category for
CD8+ T cells between the VIR and LTNP groups.
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Gene
Symbol
Accesion
No.
Description Fwd
Primer
Fwd Primer Seq Rev
Primer
Rev Primer Seq Paired
Comparison
Cell
Type
FC
qPCR
FC
MA
KLRD1 NM_002262.2 killer cell lectin-like receptor subfamily D, member 1 KLRD1L gtgggagaatggctctgc KLRD1R tttgtattaaaagtttcaaatgatgga BDLvsLTNP CD8 2.5 2.1
IRS2 NM_003749.2 insulin receptor substrate 2 IRS2L tgacttcttgtcccaccactt IRS2R catcctggtgataaagccaga BDLvsVIR CD8 3.8 2.7
GBP1 NM_002053.2 guanylate binding protein 1, interferon-inducible GBP1L aggccacatcctagttctgc GBP1R tccaggagtcattctggttgt BDLvsVIR CD8 -2.5 -2.4
ACTA2 NM_001613.1 actin, alpha 2, smooth muscle, aorta ACTA2L ctgttccagccatccttcat ACTA2R tcatgatgctgttgtaggtggt BDLvsVIR CD8 -1.3 -2.2
ATP6V1D NM_015994.2 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D ATP6V1DL ttttcactagctgaagccaagtt ATP6V1DR gcgctttattgacattttggat VIRvsLTNP CD8 2.0 2.8
BAG3 NM_004281.3 BCL2-associated athanogene 3 BAG3L cagccagataaacagtgtggac BAG3R agaggcagctggagactgg VIRvsLTNP CD8 -1.5 -2.4
ACTA2 NM_001613.1 actin, alpha 2, smooth muscle, aorta ACTA2L ctgttccagccatccttcat ACTA2R tcatgatgctgttgtaggtggt VIRvsLTNP CD8 4.3 2.8
PSMB2 NM_002794.3 proteasome subunit, beta type, 2 PSMB2L agagggcagtggaactcctt PSMB2R gaaggttggcagattcagga VIRvsLTNP CD8 1.3 2.3
PSMA5 NM_002790.2 proteasome subunit, alpha type, 5 PSMA5L tgaatgcaacaaacattgagc PSMA5R ttcttcctttgtgaacatgtgg VIRvsLTNP CD8 2.7 2.7
C1QB NM_000491.3 complement component 1, q subcomponent, B chain C1QBL ggcctcacaggacaccag C1QBR ccatgggatcttcatcatcata BDLvsVIR CD4 -4.8 -4.8
C1QC NM_172369.3 complement component 1, q subcomponent, C chain C1QCL aaggatgggtacgacggact C1QCR ttctgccctttgggtcct BDLvsVIR CD4 -5.6 -4.1
SERPING1 NM_000062.2 serpin peptidase inhibitor, clade G (C1 inhibitor),
member 1,
SERPING1L ctccttacccaggtcctgct SERPING1R ggatgctctccaggtttgtt BDLvsVIR CD4 -5.0 -2.6
C1QB NM_000491.3 complement component 1, q subcomponent, B chain C1QBL ggcctcacaggacaccag C1QBR ccatgggatcttcatcatcata VIRvsLTNP CD4 6.1 6.0
C1QC NM_172369.3 complement component 1, q subcomponent, C chain C1QCL aaggatgggtacgacggact C1QCR ttctgccctttgggtcct VIRvsLTNP CD4 7.3 4.4
SERPING1 NM_000062.2 serpin peptidase inhibitor, clade G (C1 inhibitor),
member 1,
SERPING1L ctccttacccaggtcctgct SERPING1R ggatgctctccaggtttgtt VIRvsLTNP CD4 5.3 2.8
FC_qPCR: fold change by qPCR; FC_MA: fold change by microarray.
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1versus LTNP in CD4+ T cells) along with the corre-
sponding volcano plots visualizing the number of differ-
entially expressed genes are shown in Figure 2.
Metabolic pathways associated with HIV disease
progression
In CD4+ and/or CD8+ T cells between HIV+ disease
groups, 43 metabolic pathways were significantly up-regu-
lated in the first group in at least one of the above pairwise
comparisons when comparing the first (more advanced
disease status) to the second group (less advanced disease
s t a t u s )a sl i s t e di nT a b l e5 .According to the biological
function, these 43 pathways were divided into (1) aerobic
metabolism; (2) carbohydrate and lipid metabolism; (3)
amino acid and nucleotide metabolism; and (4) protein
metabolism, respectively. Under each category, the path-
ways that showed significance across more pairwise com-
parisons were listed at the top.
In aerobic metabolism, the most generally up-
regulated pathways were tricarboxylic acid (TCA) cycle
and OXPHOS, central for cell energy production. The
OXPHOS pathway was enriched in 5/6 paired compari-
sons with FDR < 0.05, which reached the most stringent
statistical level. Closely associated with OXPHOS path-
way is the TCA cycle, which produces immediate pre-
cursor (NADH) to OXPHOS to produce ATP. The
TCA cycle was up-regulated in 4/6 paired comparisons
at the significance level of FDR < 0.1 (FDR cut off value,
normally <0.25, more stringently <0.1, most stringently
<0.05). To illustrate the up-regulation of TCA cycle in
GSEA output, the enrichment plot and heat map of the
genes involved in this pathway from the paired compari-
sons VIR versus LTNP in CD8+ T cells and BDL versus
LTNP in CD4+ T cells were shown as representatives in
Figure 3. Figure 3B in particular showed that all the
patients in the VIR group had consistent up-regulation
of TCA cycle genes when compared to the LTNP group
irrespective of the range of the viral load. Within the
VIR group, V4 and V5, with higher viral load, had even
higher expression than V1-V3, with lower viral load. To
demonstrate the location of the coordinately up-regu-
lated genes in the TCA cycle, the core enrichment
genes closely associated with the VIR group (versus
LTNP) in CD8+ T cells are shown as a representative in
Figure 4; the close linkages between TCA cycle and
other metabolic pathways including OXPHOS, carbohy-
drates, lipid, and amino acid metabolisms are also
illustrated.
In the remaining three categories, butanoate and fatty
acid metabolism were top listed in carbohydrate and
lipid metabolism. The valine, leucine, and isoleucine
degradation in nitrogen metabolism and the proteasome
involved in protein degradation were the two most sig-
nificant and generally enriched pathways besides the
OXPHOS pathway (FDR < 0.5 in four paired compari-
sons and FDR < 0.1 in one paired comparison).
Immune-related pathways associated with HIV disease
progression
In addition to the metabolic pathways, 39 immune-
related gene sets were found to be significantly up-regu-
lated in at least one of the above pairwise comparisons
(Table 6; pathways showing significance across more
pairwise comparisons are listed at top). Four outstanding
groups emerged based on the similarity of biological rele-
vance of these pathways: (1) cell cycle and apoptosis
related; (2) cytotoxicity, complement activation, and cell
signaling; (3) interleukin and interferon responses; and
(4) cytoskeleton and cell adhesion.
In the cell cycle and apoptosis category, five pathways
were directly involved in cell apoptosis including chemi-
cal pathway, apoptosis, apoptosis_genmapp, caspase
pathway, and SA_caspase_cascade (Table 6). In CD8+
T cells, the chemical pathway was significantly enriched
(FDR < 0.1) when comparing the VIR group against the
BDL/LTNP groups. In the comparison between VIR and
BDL, 15/21 genes in this pathway were core enrichment
genes associated with the VIR group, including STAT1,
BCL2L1, CASP7, TLN1, EIF2S1, BCL2, APAF1, BID,
BAX, CASP6, PXN, CASP3, PRKCB1, TP53, and AKT1
(Additional File 2). In CD4+ T cells, the apoptosis path-
way was significantly enriched (FDR < 0.1) when com-
paring the VIR group with the BDL/LTNP groups. In
comparing the VIR and LTNP groups, 25/66 genes in
this pathway were the core enrichment genes associated
with the VIR group, such as the death receptor TNFR1
(tumor necrosis factor receptor 1), cytoplasmic adaptor
TRADD, RIP1, and TRAF2, cytoplasmic effector DFF45
and DFF40, effector caspase7, and mitochondrial func-
tion genes such as BID and BCL2 (Additional File 2).
In relation to cell cycle, six pathways were significantly
up-regulated (four with FDR < 0.05 and two with FDR <
0.1) in CD8+ T cells in the VIR group (versus BDL;
Table 4 Number of enriched gene sets in pairwise
comparisons for CD4+ and CD8+ T cells using gene set
enrichment analysis (at level of FDR < 0.05 and FDR < 0.1)
FDR < 0.05 CD4 CD8 CD4 and CD8
Enriched gene sets up down up down up down
VIRvsBDL 19 3 29 2 5 2
VIRvsLTNP 27 2 8 0 6 0
BDLvsLTNP 20 7 0 1 0 1
FDR < 0.1 CD4 CD8 CD4 and CD8
Enriched gene sets up down up down up down
VIRvsBDL 57 3 53 2 18 2
VIRvsLTNP 51 4 20 0 13 0
BDLvsLTNP 31 34 0 5 0 3
Up: up-regulation; down: down-regulation; vs: versus; CD4 and CD8: gene sets
enriched in both CD4+ and CD8+ T cells in the same paired comparison.
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pathway revealed that 54/112 genes were core enrich-
ment genes and the coordinated up-regulation of these
genes appears to promote G1 to S transition and induce
arrest in G2 to M transition (Figure 5). Coordinately
up-regulated genes encoding for proteins promoting G1
to S transition include (1) 2 cyclin dependent kinase
(CDK)-cyclin complexes, CDK4/6-cyclin D and CDK2-
cyclin E; (2) 2 transcription factors E2F and DP1; (3)
DNA biosynthesis complex ORC (origin recognition
complex); (4) mini-chromosome maintenance (MCM)
complex; (5) CDC25A; and (6) S-phase kinase-associated
protein 1 and 2 (SCF and SKP2). Although a few up-
regulated genes inhibiting the transition were also
Figure 2 Gene set number plots against the FDR value from GSEA and the corresponding volcano plots visualizing the number of
differentially expressed genes. Each differentially expressed gene is represented by a blue dot. A. Volcano plot for CD4+ T cells between BDL
and LTNP groups. B. Volcano plot for CD8+ T cells between BDL and LTNP groups. C. Volcano plot for CD8+ T cells between VIR and LTNP
groups. D. Plot of gene set numbers against FDR value (BDL versus LTNP and VIR versus LTNP in CD8+ T cells, BDL versus LTNP in CD4+ T cells).
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Gene set name VvsB_CD8 VvsB_CD4 VvL_CD8 VvL_CD4 BvsL_CD4
Aerobic metabolism
HSA00190_OXIDATIVE_PHOSPHORYLATION 0.05 0.05 0.05 0.05 0.05
HSA00020_CITRATE_CYCLE 0.1 0.1 0.1 0.1
HSA00760_NICOTINATE_AND_NICOTINAMIDE_METABOLISM 0.05 0.05 0.1 0.05
TYPE_III_SECRETION_SYSTEM 0.05 0.05 0.05
PHOTOSYNTHESIS 0.05 0.05 0.05
ATP_SYNTHESIS 0.05 0.05 0.05
FLAGELLAR_ASSEMBLY 0.05 0.05 0.05
MITOCHONDRIAL_FATTY_ACID_BETAOXIDATION 0.1 0.1
PYRUVATE_METABOLISM 0.1 0.05
Carbohydrate and lipid metabolism
HSA00650_BUTANOATE_METABOLISM 0.05 0.1 0.05 0.05
HSA00071_FATTY_ACID_METABOLISM 0.05 0.05 0.05
HSA00670_ONE_CARBON_POOL_BY_FOLATE 0.1 0.1 0.1
HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM 0.1 0.1 0.1
HSA00511_N_GLYCAN_DEGRADATION 0.05 0.05 0.1
HSA00030_PENTOSE_PHOSPHATE_PATHWAY 0.1 0.1
HSA01032_GLYCAN_STRUCTURES_DEGRADATION 0.05 0.05
STARCH_AND_SUCROSE_METABOLISM 0.05 0.1
HSA00052_GALACTOSE_METABOLISM 0.1 0.1
HSA00532_CHONDROITIN_SULFATE_BIOSYNTHESIS 0.1 0.05
PROPANOATE_METABOLISM 0.05
HSA00040_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS 0.1
HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS 0.1
GLYCOLYSIS 0.1
GLUCONEOGENESIS 0.1
HSA00710_CARBON_FIXATION 0.1
PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM 0.1
BILE_ACID_BIOSYNTHESIS 0.05
HSA00531_GLYCOSAMINOGLYCAN_DEGRADATION 0.1
HSA00565_ETHER_LIPID_METABOLISM 0.1
FRUCTOSE_AND_MANNOSE_METABOLISM 0.1
Amino acid and nucleotide metabolism
HSA00280_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 0.05 0.1 0.05 0.05 0.05
LYSINE_DEGRADATION 0.05 0.1 0.05 0.05
HSA00230_PURINE_METABOLISM 0.05 0.1 0.1 0.1
PHENYLALANINE_METABOLISM 0.1 0.05 0.05 0.1
HSA00380_TRYPTOPHAN_METABOLISM 0.1 0.1 0.05 0.1
HSA00240_PYRIMIDINE_METABOLISM 0.05 0.1 0.05
HSA00252_ALANINE_AND_ASPARTATE_METABOLISM 0.1 0.1 0.05
HSA00410_BETA_ALANINE_METABOLISM 0.05 0.1
PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 0.05 0.1 0.05 0.1
HSA00330_ARGININE_AND_PROLINE_METABOLISM 0.1
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of DNA biosynthesis complexes suggested directly pro-
moted transition. Associated with G2 to M transition,
we observed up-regulated genes encoding for proteins
that generally prevent the cell cycle, including (1) the
protein kinases WEE1 and MYT1, which inactivate the
complex CDK1-cyclin B pivotal in regulating G2 to M
transition; (2) protein 14-3-3 which inactivates CDC25
phosphatase required for CDK1 activation; (3) DNA-PK
activated by DNA damage and CHK kinases which inac-
tivates CDC25; (4) p53 which turns on the expression of
GADD45 and 14-3-3s, both prevent the activity of
CDK1-cyclin B.
In the category of cytotoxicity, complement activation
and cell signaling, pathways of antigen processing and
presentation and cell cytotoxicity were significantly
enriched in both CD4+ and CD8+ T cells when the VIR
group was compared to the BDL group (FDR < 0.05;
Table 6). Three complement-associated pathways
COMPPATHWAY, HSA04610 complement and coagu-
lation-cascades, and intrinsic pathway as well as toll
receptor signaling pathway were significantly and
uniquely enriched in CD4+ T cells of the VIR group
(versus BDL/LTNP; FDR < 0.05/0.1; Table 6). Further
inspection of HSA04610 pathway revealed 18/68 genes
were core enrichment genes (Additional File 3).
In the cytoskeleton and cell adhesion category, the
RHO pathway was significantly enriched in both CD4+
and CD8+ T cells in the more advanced disease group
in four paired comparisons with FDR < 0.05 (Table 6).
This pathway is involved in cytoskeleton reorganization,
reported to enhance virus fusion to host cell membranes
[25]. In the category of interleukin and interferon
responses, IL3, IL6, and IL12 pathways were found to be
enriched in either CD4+ or CD8+ T cells when the VIR
group was compared to the BDL group. For the same
paired comparison, the TIDPATHWAY involved in
interferon-g stimulating anti-viral responses was
enriched in CD4+ T cells from the VIR group.
Relatively few pathways were significantly up-regulated
in the second group (BDL or LTNP) in pairwise
comparisons of the VIR versus BDL, VIR versus LTNP,
and BDL versus LTNP groups. However, it was noted
that the comparison of BDL versus LTNP in CD4+
T cells gave 7 and 27 pathways enriched in the LTNP
group at the statistical level of FDR < 0.05 and FDR < 0.1,
respectively (Table 7). Out of these 34 gene sets, 15 were
closely associated with the MAPK pathway and 10 with
cell signaling such as TCR and chemokine and cytokine
pathways.
Unique pathways associated with non-progressive HIV
disease
Among the 15 MAPK-associated pathways significantly
enriched in the LTNP group (BDL versus LTNP) for
CD4+ T cells, the NTHI, JNK MAPK, and granule cell
survival pathways are the top three gene sets with FDR <
0.05. In the LTNP group, core enrichment genes in the
NTHI pathway were MAP2K3 (MEK3) located along the
MAPK p38 cascade and NFKBIA associated with NFKB
activation (Figure 6, Additional File 2), indicating the up-
regulation of p38 pathway. In JNK MAPK and granule
cell survival pathway, MAPK9( J N K 2 )a n di t su p s t r e a m
kinase MAP2K7 (MKK7) were found to be core enrich-
ment genes (Figure 6, Additional File 2), indicating the
up-regulation of JNK pathway. Overlapping analysis of
core enrichment genes between IGF1, insulin, and NGF
pathways (FDR≤0.05) revealed eight common core
enrichment genes (GRB2, PIK3R1, PIK3CA, HRAS,
MAP2K1, ELK1, JUN, and FOS). These overlapping
genes are involved in the ERK signal transduction cas-
cade, another branch of the MAPK signaling pathway
(Figure 6). All the aforementioned MAPK associated
pathways are also top ranked in the LTNP group in other
pairwise comparisons, although they do not reach the
highest statistical significance level (Additional File 4).
In the top ranked but less statistically significant gene
sets, AKTPATHWAY and WNT signaling pathways are
closely associated with cell survival. Comparing VIR ver-
sus LTNP for CD4+ T cells, both pathways were
enriched in the LTNP group (FDR = 0.23). In the AKT-
PATHWAY, core enrichment genes included PIK3R1,
PIK3CA, and PPP2CA involved in AKT activation,
Table 5 Enriched gene sets involved in energy production (Continued)
Protein metabolism
PROTEASOME 0.05 0.1 0.05 0.05 0.05
PROTEASOMEPATHWAY 0.1 0.1 0.1
HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS 0.05 0.1
VvsB_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD8+ T cells.
VvsB_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD4+ T cells.
VvL_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD8+ T cells.
VvL_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD4+ T cells.
BvsL_CD4: Gene sets enriched in the BDL group in the comparison of BDL versus LTNP in CD4+ T cells.
Gene sets significantly enriched are marked by the number 0.05 or 0.1 in the corresponding paired comparisons 0.05: FDR < or = 0.05; 0.1: FDR < or = 0.1.
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp.
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Page 9 of 21Figure 3 Enrichment plot and heat map for the gene set of tricarboxylic acid cycle by GSEA. A. Enrichment plot for CD8+ T cells from
the VIR group (VIR versus LTNP). Bottom, plot of the ranked list of all genes. Y axis, value of the ranking metric; X axis, the rank for all genes.
Genes whose expression levels are most closely associated with the VIR or LTNP group get the highest metric scores with positive or negative
sign, and are located at the left or right edge of the list. Middle, the location of genes from the gene set TCA cycle within the ranked list. Top,
the running enrichment score for the gene set as the analysis walks along the ranked list. The score at the peak of the plot is the enrichment
score (ES) for this gene set and those genes appear before or at the peak are defined as core enrichment genes for this gene set. B. Heat map
of the genes within the gene set of TCA cycle corresponding to A. The genes that contribute most to the ES, i.e., genes that appear in the
ranked list before or at the peak point of ES, are defined as core enrichment genes and highlighted by the red rectangle. Rows, genes, columns,
samples. Range of colors (red to blue) shows the range of expression values (high to low). C. Enrichment plot for CD4+ T cells from the BDL
group (BDL versus LTNP). D. Heat map of the genes within the gene set of TCA cycle corresponding to C.
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Page 10 of 21transcription factors associated with cell survival
NFKB1, NFKB1A, RELA, FOXO1A, and FOXO3A
(Additional File 2). In the WNT pathway, some key
genes were detected as core enrichment genes including
W N T 1 ,W N T1 0 A ,W N T 1 0 B ,F Z D 6 ,D V L 3 ,T C F 7 ,a n d
CTNNB1 (b-catenin; Additional File 2).
Discussion
An analysis of the CD4+ and CD8+ T cell transcriptomes
from three different HIV disease groups was undertaken
to identify gene expression signatures associated with dis-
ease progression. All the enriched categories derived
from GO enrichment analysis of DE genes corresponded
to certain enriched pathways detected by GSEA, confirm-
ing the statistical reliability of our analyses. For example,
the enriched GO category complement activation corre-
sponded to the enriched pathway HSA04610 comple-
ment and coagulation cascades in the comparison of VIR
versus BDL/LTNP for CD4+ T cells and the enriched
GO category proton-transporting ATPase complex corre-
sponded to the enriched OXPHOS pathway in the VIR
versus LTNP comparison for CD8+ cells. Also, GSEA
detected more comprehensive pathways correlated with
disease progression. Among these enriched pathways,
mitochondrial function emerged as a major theme during
disease progression as a large portion of the enriched
pathways for various physiological processes were all clo-
sely associated. These pathways, functionally connected
to mitochondria, formed a network directly related to
HIV disease progression as discussed below (Figure 7).
Figure 4 Coordinately up-regulated TCA cycle genes in CD8+ T cells from the VIR group (VIR versus LTNP) illustrated in TCA cycle
pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The enzymes encoded by coordinately
up-regulated TCA cycle genes are highlighted in red and these include ATP citrate lyase (EC:2.3.3.8; gene symbol ACLY), aconitase 1, soluble and
aconitase 2, mitochondrial (EC:4.2.1.3; gene symbol ACO1 and ACO2), isocitrate dehydrogenase 2 (NADP+), mitochondrial (EC:1.1.1.42; gene
symbol IDH2), isocitrate dehydrogenase 3 (NAD+) gamma (EC:1.1.1.41; gene symbol IDH3G), oxoglutarate (alpha-ketoglutarate) dehydrogenase
(EC:1.2.4.2; gene symbol OGDH), succinate-CoA ligase, alpha subunit (EC:6.2.1.4; gene symbol SUCLG1), succinate-CoA ligase, ADP-forming, beta
subunit (EC:6.2.1.5; gene symbol SUCLG2), succinate dehydrogenase complex, subunit C (EC:1.3.5.1; gene symbol SDHC), fumarate hydratase
(EC:4.2.1.2; gene symbol FH), malate dehydrogenase 1 and 2, (EC:1.1.1.37; gene symbol MDH1 and MDH2), and phosphoenolpyruvate
carboxykinase 2 (mitochondrial) (EC:4.1.1.32; gene symbol PCK2). Coordinately up-regulated pathways, which are closely articulated with the TCA
cycle, are highlighted by red rectangles. The TCA cycle intermediates linked to other pathways are highlighted by red circles.
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Page 11 of 21Table 6 Enriched gene sets other than involved in energy production
Gene set name VvsB_CD8 VvsB_CD4 VvL_CD8 VvL_CD4 BvsL_CD4
Cell cycle and apoptosis related
CHEMICALPATHWAY 0.1 0.1
APOPTOSIS 0.1 0.1
APOPTOSIS_GENMAPP 0.1
CASPASEPATHWAY 0.1 0.05
SA_CASPASE_CASCADE 0.05
DNA_REPLICATION_REACTOME 0.05 0.05 0.1
G1_TO_S_CELL_CYCLE_REACTOME 0.05
HSA04110_CELL_CYCLE 0.05
CELL_CYCLE_KEGG 0.05
CELLCYCLEPATHWAY 0.05
G2PATHWAY 0.1
G1PATHWAY 0.1
P53PATHWAY 0.1
MPRPATHWAY 0.1
ST_GA12_PATHWAY 0.05
Cytotoxicity, complement activation and cell signalling
HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION 0.05 0.05 0.05
HSA04650_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 0.05 0.05 0.05
COMPPATHWAY 0.05 0.05 0.05
HSA04610_Complement_and_coagulation-cascades 0.05 0.05
INTRINSICPATHWAY 0.1 0.1
HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 0.05 0.1
TOLLPATHWAY 0.05
HSA04662_B_CELL_RECEPTOR_SIGNALING_PATHWAY 0.1
SA_B_CELL_RECEPTOR_COMPLEXES 0.1
Cytoskeleton and cell adhesion
RHOPATHWAY 0.05 0.05 0.05 0.05
NDKDYNAMINPATHWAY 0.1
SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES 0.1
INTEGRIN_MEDIATED_CELL_ADHESION_KEGG 0.1
Interleukin
IL12PATHWAY 0.1
NO2IL12PATHWAY 0.1
TIDPATHWAY 0.1
IL6PATHWAY 0.1
IL3PATHWAY 0.1
Other
SPPAPATHWAY 0.1
HSA05120_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION 0.05
HSA05131_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EPEC 0.1
HSA05130_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC 0.1
HSA04320_DORSO_VENTRAL_AXIS_FORMATION 0.1
HSA05219_BLADDER_CANCER 0.1
VvsB_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD8+ T cells.
VvsB_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD4+ T cells.
VvL_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD8+ T cells.
VvL_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD4+ T cells.
BvsL_CD4: Gene sets enriched in the BDL group in the comparison of BDL versus LTNP in CD4+ T cells.
Gene sets significantly enriched are marked by the number 0.05 or 0.1 in the corresponding paired comparisons 0.05: FDR < or = 0.05; 0.1: FDR < or = 0.1.
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp.
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signature evoked by mitochondria dysfunction in HIV
disease progression
Forty-three up-regulated metabolic pathways were
detected as transcriptional signatures in the relatively
more advanced HIV cases. These signatures were high-
lighted by the TCA cycle and OXPHOS pathways along
with a series of degradation pathways of carbohydrates,
fatty acids, and amino acids, articulating with the TCA
cycle by furnishing substrates. Interestingly, this compre-
hensive and unambiguous expression signature in ex vivo
patient-derived T cells is consistent with two recent CD4+
T cell-line-based proteomic studies which also demon-
strated the up-regulation of components of OXPHOS,
TCA cycle, amino acid metabolism, and fatty acid metabo-
lism at the protein level in human CD4+ T cell lines after
HIV infection [26,27]. The proteomic study, using cell
lines, and our transcriptome study, using primary patient
cells, are complementary, implying the functional
significance of our observations. Further, the detection of
the OXPHOS pathway as the most significantly enriched
gene set for both CD4+ and CD8+ T cells is also in line
with earlier work, which identified OXPHOS pathway up-
regulation a distinct transcriptional feature in CD8+
T cells unique to the VIR group when compared against
the versus the LTNP group [20]. Moreover, by simulta-
neously comparing both CD4+ and CD8+ T cells from
three HIV disease groups, this study further extends pre-
vious findings to provide a panoramic view of all the con-
cordantly regulated metabolic pathways in conjunction
with OXPHOS pathway. To our knowledge, this study is
the first to show this metabolic transcriptional signature in
primary CD4+ and CD8+ T cells, in relation to HIV dis-
ease progression. We hypothesize that the up-regulation
of these metabolic pathways could be a compensatory
event evoked by mitochondrial dysfunction incurred by
HIV infection and HAART. This hypothesis is based on
the fact that mitochondria are the organelles where the
Figure 5 Coordinately up-regulated cell cycle genes in CD8+ T cells from the VIR group (VIR versus BDL) illustrated in cell cycle
pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins encoded by coordinately up-
regulated cell cycle genes are highlighted in red.
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Page 13 of 21TCA cycle, OXPHOS, and downstream biochemical reac-
tions of degraded products are taking place and mitochon-
drial dysfunction in HIV disease has been well
documented [28]. The NRTIs can inhibit the major
mtDNA polymerase [29], induce mtDNA mutations [30],
and impair mitochondrial enzymes such as adenylate
kinase and the ADP/ATP translocator [31,32]. In addition,
the HIV accessory proteins Vpr and Tat, and the HIV pro-
tease (Pr) could modulate mitochondrial membrane per-
meabilization by various pathways involving protein BAX,
BAK, BCL-2, and adenine nucleotide translocase (ANT)
[33-35].
The hypothesis that metabolic pathways are a com-
pensatory event evoked by mitochondrial dysfunction is
further supported by the high similarity between this
data and the gene expression profiles from study of
compensatory events in primary mitochondrial dysfunc-
tion [36]. Using the electron transport chain complex I
mutant of Caenorhabditis elegans as a model, 29 up-
regulated metabolic pathways characterizing the cellular
compensatory events accompanying mitochondrial dys-
function were identified [36], of which 15 (> 50%) were
shared with our list.
Pathways involved in mitochondria-mediated cell
apoptosis
T h es i g n i f i c a n c eo fm i t o c h o n d r i a ld y s f u n c t i o ni nH I V
disease progression is further strengthened by the
detection of coordinately up-regulated genes involved in
mitochondria-mediated cell apoptosis in both CD4+ and
CD8+ T cells. This is exemplified by the 15 core-enrich-
ment genes in the chemical pathway detected in the
CD8+ T cells in the comparison between VIR and BDL
groups. For instance, TP53, BAX, and BID could alter
the mitochondrial membrane permeability; APAF1 is
involved in initiating effector caspase-mediated cell
death; CASP3, CASP6, and CASP7 are the effector cas-
pases which cleave substrates leading to modified signal-
ing, and the downstream substrates of these caspases
including STAT1, EIF2S1, TLN1 (talin 1), PXN (paxil-
lin), and PRKCB1 (protein kinase C), which eventually
lead to cell apoptosis. These genetic level observations
were consistent with previous studies at the cellular
level showing that the LTNPs had milder mitochondrial
impairment and low numbers of cells with reduced
mitochondrial membrane potential; this correlates with
lower frequency of spontaneous apoptosis and higher
frequencies of CD4+ T cells when compared to AIDS
patients [37,38].
In addition, the detection of G2 arrest along with the
chemical pathway in CD8+ T cells in the VIR group
(versus BDL) led to the further speculation that G2
arrest may be functionally linked to mitochondria-
mediated cell apoptosis. The HIV protein Vpr induces
cell cycle arrest in the G2/M checkpoint in both CD4+
T cells and macrophages [39,40], and there might be a
direct correlation between G2 arrest and cell apoptosis
[41]. The activation of BAX, the pore-forming mito-
chondrial protein, has been suggested as the functional
linkage between G2 arrest and cell apoptosis [42].
It was unique that in addition to the linkage between
G2 arrest and mitochondria-mediated cell apoptosis, the
AKT pathway top ranked for the LTNP group (Addi-
tional File 4) negatively regulated the chemical pathway
by blocking mitochondria-mediated cell apoptosis,
which could contribute to cell survival in LTNPs. In the
AKT pathway, genes associated with AKT activation
including PIK3R1, PIK3CA, and PPP2CA were coordi-
nately up-regulated in the LTNP group (versus VIR) in
CD4+ and CD8+ T cells. Activated AKT is known to
promote cell survival by phosphorylating BAD and
CASP9 to inhibit pore-forming in mitochondria mem-
branes and prevent the subsequent caspase cascade,
respectively [43]. Additionally, in the AKT pathway the
FOXO factors (FOXO1A, and FOXO3A) detected as
core enrichment genes could also contribute to cell sur-
vival, as these transcription factors are involved in cell
survival [44].
Taken together, a network of pathways closely asso-
ciated with HIV disease progression was constructed
(Figure 7). Centrally located is mitochondrial dysfunc-
tion, which interferes with various other pathways
Figure 6 Branches of MAPK pathway significantly enriched in
CD4+ T cells from the LTNP group (BDL versus LTNP). Listed
genes except for p38 and ERK1/2 are the core enrichment genes
derived from MAPK associated pathways and directly involved in
the MAPK cascade. The possible roles of each branch of MAPK
pathway contributing to the LTNP status are also shown.
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cycle dysregulation and mitochondria-meditated cell
apoptosis. In addition, the mitochondria-mediated cell
apoptosis could be blocked by the AKT pathway
enriched in the LTNP group. Consistent with our analy-
sis, two large scale studies of HIV-host interactions by
siRNA screening also identified a link between mito-
chondrial function and HIV replication [45,46]. In addi-
tion, Zhou et al. have identified the AKT-associated
pathway in HIV replication in association with cellular
energy metabolism and cell survival, which is well in
line with our data.
Table 7 Enriched pathways in CD4+ T cells from the LTNP group (BDL versus LTNP)
Gene set name Gene set size NES NOM p-val FDR
MAPK pathway associated
NTHIPATHWAY 22 -2.05 0.000 0.008
ST_JNK_MAPK_PATHWAY 40 -1.88 0.002 0.038
ST_GRANULE_CELL_SURVIVAL_PATHWAY 26 -1.77 0.002 0.049
IGF1PATHWAY 20 -1.77 0.002 0.049
INSULINPATHWAY 21 -1.79 0.004 0.050
NGFPATHWAY 19 -1.81 0.002 0.053
CARDIACEGFPATHWAY 17 -1.75 0.000 0.056
41BBPATHWAY 18 -1.74 0.014 0.058
CDMACPATHWAY 16 -1.71 0.010 0.073
HSA04012_ERBB_SIGNALING_PATHWAY 87 -1.70 0.008 0.074
SA_TRKA_RECEPTOR 16 -1.70 0.012 0.075
HSA04010_MAPK_SIGNALING_PATHWAY 256 -1.64 0.000 0.087
PDGFPATHWAY 27 -1.66 0.012 0.088
TPOPATHWAY 23 -1.66 0.012 0.089
EGFPATHWAY 27 -1.66 0.018 0.091
Cell signaling
INFLAMPATHWAY 29 -1.99 0.000 0.017
CYTOKINEPATHWAY 20 -1.95 0.000 0.023
CCR5PATHWAY 18 -1.78 0.006 0.049
TCRPATHWAY 43 -1.80 0.006 0.052
IL6PATHWAY 21 -1.79 0.002 0.054
IL1RPATHWAY 32 -1.82 0.000 0.055
IL12PATHWAY 20 -1.68 0.018 0.083
TOLLPATHWAY 34 -1.66 0.012 0.086
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 253 -1.65 0.000 0.087
HSA04660_T_CELL_RECEPTOR_SIGNALING_PATHWAY 93 -1.65 0.006 0.089
CALCINEURIN_NF_AT_SIGNALING 92 -1.92 0.000 0.030
Other
HYPERTROPHY_MODEL 17 -1.91 0.000 0.025
ATMPATHWAY 19 -1.86 0.000 0.043
HSA05210_COLORECTAL_CANCER 85 -1.78 0.000 0.049
SMOOTH_MUSCLE_CONTRACTION 140 -1.83 0.000 0.051
CIRCADIAN_EXERCISE 40 -1.79 0.000 0.051
GPCRPATHWAY 35 -1.76 0.006 0.054
ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS 42 -1.73 0.002 0.064
P53HYPOXIAPATHWAY 19 -1.68 0.022 0.082
Gene set size: number of genes in a particular gene set; NES: normalized enrichment score.
NOM p-val: nominal p value; FDR: false discovery rate.
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp.
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The significant up-regulation of gene sets closely asso-
ciated with three branches of MAPK pathway (ERK,
JNK, and p38) in LTNPs could contribute to cell survi-
val as well as stronger anti-HIV responses. In relation to
cell differentiation and activation, JNK and p38 are criti-
cal for naïve CD4+ T cell differentiation into the Th1
subset, which antagonizes Th2 subset switch associated
with HIV disease progression [3]. Activation of the p38
pathway also results in increased IFN-g production by
both CD4+ and CD8+ T cells, plays an important role
in T cell homeostasis by selectively inducing CD8+, but
not CD4+ T cell death via modulation of BCL-2 expres-
sion [47,48]. ERK is required for Th2 differentiation and
the cytotoxic activity of most CD8+ T cells [49]. The
ERK pathway could be activated by its upstream signal-
ing pathway, the T-cell receptor pathway, which is also
up-regulated in the LTNP group. Supporting this specu-
lation, components of TCR complex CD3epsilon, and
ZAP70 (TCR zeta-chain associated protein kinase) as
well as genes involved in ERK activation, HRAS (RAS)
and MAP2K1 (MEK1), were detected as the core enrich-
ment genes in the T-cell receptor pathway. Further con-
firmation came from our previous antibody/protein
microarray study showing that CD3epsilon expression
was significantly higher in LTNP than in the VIR group
on CD4+ T cells [20].
Besides direct involvement, the MAPK pathway inter-
acts with a range of pathways critical for cell function
and survival, such as p53 and WNT signaling pathways.
The top ranked WNT pathway in the LTNP group
(Additional File 4) indicated a possible role of this path-
way in cell survival; another study has shown that
MAPK-p38 pathway regulates WNT-b-catenin signaling
[50].
Critical differences segregating CD4+ and CD8+ T cell
transcriptomes during HIV disease
Contrasting with hundreds of differentially expressed
genes in CD8+ T cells in the VIR group (versus LTNP),
the comparison of BDL versus LTNP revealed only four
differentially expressed genes and one enriched gene set,
which indicated that the transcriptional profile largely
remained unaltered in CD8+ T cells from BDL patients.
For the same paired comparison in the CD4+ T cells,
although only three differentially expressed genes were
detected, 27 enriched gene sets have reached the signifi-
cance level of FDR < 0.05, which implied the shift of
transcriptome profile in CD4+ T cells from BDL
patients. Supporting this, an independent study has
shown that distinct transcriptional profiles in both CD4
+ and CD8+ T cells are established early in HIV infec-
tion by comparing between early infection, chronic pro-
gressive infection, and non-progression groups [19].
However, the study subjects in this study were grouped
by the duration of HIV infection, but not on the plasma
HIV load levels (the patients from the early infection
group already had detectable viral loads). On the other
hand, Hyrcza’s data demonstrated that with various viral
load levels, even if the infection duration was as short as
1-5 months, the CD8+ T cell transcriptional profile
could be shifted. Taken together, these datasets appear
to show a close correlation between the beginning of
detectable plasma viral load and transcriptome shift
uniquely in CD8+ T cells. This was not the case for
CD4+ T cell transcriptomes. This study, from the gene
and gene set level, further confirmed our recent findings
that the CD8+ T cell transcriptome profiles shift only
Figure 7 Schematic overview of the network of enriched
pathways related to HIV disease progression. HIV accessory
proteins and side effects of therapy could lead to the impaired
activity of electron transport chain complex I, which results in
mitochondrial dysfunction. As a compensatory effect, OXPHOS
pathway (electron transport chain and ATP synthase) is up-regulated
as indicated by the red arrow. Along with the OXPHOS pathway,
the TCA cycle supplying NADH to OXPHOS, and a wide range of
metabolic pathways (carbohydrate, fatty acid, protein, and amino
acid metabolism pathways) furnishing substrates to the TCA cycle
are coordinately up-regulated. In addition, mitochondrial
dysfunction leads to cell apoptosis mediated by the activation of
mitochondrial membrane pore-forming proteins, such as BAX and
BAD. Pores generated in the mitochondrial membranes allow the
release of the pro-apoptotic proteins cytochrome c, which binds to
APAF and hence activates CASP9 leading to the caspase cascade
resulting in apoptosis. G2 arrest and DNA damage signaling could
also activate BAX leading to mitochondria-mediated apoptosis. On
the other hand, AKT could prevent apoptosis by either inhibiting
BAD or CASP9 activation or preventing FOXO factors from
relocating to the nucleus.
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Page 16 of 21when a viral load is above the certain as yet unknown
threshold level [21].
Another transcriptional signature unique to CD4+
T cells is the complement activation in the VIR group
(versus BDL/LTNP) detected by both differentially
expressed genes analysis and GSEA. This was exempli-
fied by HSA04610 complement and coagulation-
cascades pathway; the coordinately up-regulated core
enrichment genes include those encoding for the com-
plement proteins and complement receptors (Additional
F i l e3 ) ,b u tn o tt h el y t i cp a t h w a yg e n e s( C 6 ,7 ,8 ,9 ) .
This is consistent with studies showing that HIV acti-
vates the complement cascades, but avoids the lysis via
complement regulatory molecules [51,52]. Interactions
between HIV envelope protein gp41 and C1Q lead to
the complement activation independent of HIV-specific
antibodies [53] and the sequentially generated C3 frag-
ments (C3b, iC3b, and C3d) linked to HIV could have
high affinity interaction with complement receptors on a
wide range of cells such as B cells, macrophages, and
follicular dendritic cells [51,54]. In line with these stu-
dies, our data strengthens the close association between
up-regulated complement activation and HIV disease
progression at the genetic level in primary CD4+
T cells, and the impacts of innate immunity on HIV
pathogenesis warrants further investigation. Together,
these observations imply that different cell subsets differ
in their pace towards disease progression and the way
they maintain distinct immunologic interaction with
HIV during the disease course. Thus, the specific HIV
disease stage may bear cell type-specific transcriptomic
signatures, which is evident from this study.
Conclusions
In summary, this study is the first to identify a network
of a large panel of pathways functionally connected by
mitochondria as a transcriptional signature of HIV dis-
ease progression in primary CD4+ and CD8+ T cells.
This signature contains 43 metabolic pathways closely
articulated with TCA cycle and OXPHOS pathways
pointing towards mitochondrial dysfunction. The signifi-
cance of mitochondrial dysfunction is further strength-
ened by the detection of coordinately up-regulated
genes involved in mitochondria-mediated cell apoptosis
in both CD4+ and CD8+ T cells in the VIR group (VIR
versus BDL). Mitochondria-mediated cell apoptosis is
negatively regulated by the AKT pathway top ranked for
the LTNP, which could contribute to cell survival in the
LTNPs. Along with the AKT pathway, MAPK and
WNT pathways are also closely associated with the
LTNPs, which may contribute to cell survival and stron-
ger anti-viral responses via Th1 polarization, IFN-g reg-
ulation, and cytotoxicity activity. Comparisons between
CD4+ and CD8+ T cells revealed that the CD8+ T cell
transcriptome shifts after the viral load becomes detect-
able, but this occurs earlier in CD4+ T cell transcrip-
tomes. Another transcriptional signature unique to CD4
+ T cells is the complement activation in the VIR group
versus BDL/LTNP. Overall, these data offer new com-
parative insights into HIV disease progression from the
aspect of HIV-host interactions at the transcriptomic
level, which will facilitate the understanding of the
genetic basis of transcriptomic interaction of HIV
in vivo and how HIV subverts the human gene machin-
ery at the individual cell type level. Further studies on
the regulation of these pathways and the corresponding
core enrichment genes may provide a detailed under-
standing of the molecular mechanisms involved, which
may also aid the development of therapeutic interven-
tions. Future therapeutic interventions aiming at preser-
ving mitochondrial function could be clinically
beneficial. Building up database of the pathway interac-
tions will definitely aid the understanding of the inter-
connections between various pathways, which will
ultimately enable the integration of various molecular
mechanisms into a system level.
Methods
Patient profiles and collection protocol
Four HIV infected long-term non-progressors (LTNP;
n=4 ) ,f i v eH I V +p a t i e n t so nH A A R Tw i t hb e l o w
detectable level of plasma viremia (BDL; n = 5), and five
viremic HIV+ patients on HAART (VIR; n = 5) along
with five healthy HIV seronegative individuals (NEG; n
= 5) were studied. No single individual had CCR5-Δ32
homozygous mutation and there is no statistically signif-
icant difference in the prevalence of CCR5-Δ32 hetero-
zygous between the study groups. The infection time for
L1, L2 and L3 are >20 years, and L4 >14 years. These
treatment-naïve LTNPs have maintained high CD4+
T cell counts (> 500 cells/μl) and below detectable
plasma viremia (< 50 HIV RNA copies/ml plasma)
except one patient (L4) with very low plasma viremia
(57 HIV RNA copies/ml plasma) (Table 1). Patients in
the VIR group were on HAART and had detectable
plasma viremia and CD4+ T cell counts <500 cells/μl,
whereas patients in the BDL group showed no detect-
able viremia while on HAART. These patients received
two NRTIs (zidovudine, lamivudine, stavudine, emtrici-
tabine, tenofovir) in association with one or two pro-
tease inhibitors (darunavir, ritonavir, indinavir,
saquinavir, atazanavir). Eleven patients came from the
HIV clinic at Westmead Hospital and three patients
p l u st h ef i v eh e a l t h yc o n t r o l sc a m ef r o mt h eA u s t r a l i a n
Red Cross Blood Service in Sydney. This study was
approved by the Sydney West Area Health Services
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collected after individual informed written consent.
Purification of CD4+ and CD8+ T cells and RNA isolation
A single blood sample (10-20 ml in EDTA) was
obtained from each patient. After separation of plasma,
PBMC were isolated immediately after obtaining blood
samples by Ficoll-gradient centrifugation and purified.
This aspect was strictly followed in our experiments
because of previously described lower RNA yields and
possible changes in gene expression profiles upon sto-
rage of blood [55]. CD4+ and CD8+ T cells were then
obtained by positive isolation with antibody-conjugated
magnetic beads according to the manufacturer’s instruc-
tions (Dynal Biotech, Oslo, Norway). Flow-cytometric
analysis performed on separated CD4+ and CD8+ T cell
populations demonstrated that 99.2% ± 0.165 (mean
±SD) and 99.1% ± 0.128 (mean ±SD) of purified CD4+
and CD8+ cells were single positive for the CD4 and
CD8 marker, respectively [56]. In positively isolated
CD8+ cell population, >97% cells were CD3 positive as
shown by flow cytometry in a previous study [18]. Thus,
the very low percentage of NK cells in CD8+ cell popu-
lation would have negligible effect on the results. Total
RNA was isolated from purified cells using RNeasy Mini
kit (Qiagen Pty Ltd., Clifton Hill, Victoria, Australia)
with an integrated step of on-column DNase treatment.
cRNA preparation, microarray hybridization and scanning
RNA quality was checked by Agilent Bioanalyzer and
RNA Integrity Scores are higher than 7 for all the sam-
ples. cRNA amplification and labeling with biotin were
performed using Illumina TotalPrep RNA amplification
kit (Ambion, Inc., Austin, USA) with 250 ng total RNA
as input material. cRNA yields were quantified with Agi-
lent Bioanalyzer and 1.5 μg cRNAs were hybridized to
the Sentrix Human-6 v2 Expression BeadChips (Illu-
mina, Inc., San Diego, USA). Each chip contains six
arrays and each array contains >48,000 gene transcripts,
of which, 46,000 derived from human genes in the
National Center for Biotechnology Information (NCBI)
Reference Sequence (RefSeq) and UniGene databases.
All reagents and equipment used for hybridization were
purchased from Illumina, Inc. According to the manu-
facturer’s protocol, cRNA was hybridized to arrays for
16 hours at 58°C before being washed and stained with
streptavidin-Cy3. Then the beadchips were centrifuged
to dry and scanned on the Illumina BeadArray Reader
confocal scanner.
Analysis of differentially expressed genes
The quality of the entire data set was assessed by box
plot and density plot of bead intensities, density plot of
coefficient of variance, pairwise MAplot, pairwise plot
with microarray correlation, cluster dendrogram, and
non-metric multidimensional scaling (NMDS) using R/
Bioconductor and the lumi package [22]. Based on the
quality assessment, all 38 samples were deemed suitable
for further analysis. Data normalization was performed
using a variance-stabilising transform (VST) and a
robust spline normalization (RSN) implemented in the
lumi package for R/Bioconductor [22,57]. To reduce
false positives, unexpressed genes (based on a detection
p value cut-off 0.01) were removed from the dataset. A
linear model fit in conjunction with an empirical Bayes
statistics were used to identify candidate differentially
expressed (DE) genes [23]. Adjustment for multiple test-
ing was performed using the Bonferroni adjustment. For
both CD4+ and CD8+ T cells, pairwise comparisons
from the 4 study groups (BDL vs NEG, VIR vs NEG,
LTNP vs NEG, BDL vs LTNP, VIR vs LTNP, BDL vs
VIR) were carried out and candidate DE genes with fold
change >2 and B-statistic > 0 were identified for each of
the comparisons.
To identify the enriched functional categories from
the DE genes, Gene Ontology (GO) Tree from WebGes-
talt (Web-based Gene SeT AnaLysis Toolkit) was used
to identify GO categories with significantly enriched
gene numbers [58]. The hypergeometric test was used
to calculate the statistic for each category and all genes
from human were used as the reference gene set. GO
categories with at least 2 genes and p < 0.01 are identi-
fied as enriched and colored red in the GOTree. In
GOTree, O stands for observed gene number in the
category; E for expected gene number in the category; R
for ratio of enrichment for the category; and P for p
value calculated from the statistical test given for the
categories with R > 1 to indicate the significance of
enrichment.
Gene set enrichment analysis
To further understand the biological meanings underly-
ing the transcriptome data from various HIV+ disease
groups, a complement approach, gene set enrichment
analysis (GSEA) was used [24]. Instead of selecting sin-
gle DE genes, this method analyzed the entire transcrip-
tome data to identify genes coordinately regulated in
predefined gene sets from various biological pathways.
For each pairwise comparison (BDL versus LTNP, VIR
versus LTNP, BDL versus VIR) for both CD4+ and CD8
+ T cells, GSEA was performed using the normalized
data of entire 48,000 transcripts (GSEA version 2.0,
Broad Institute http://www.broad.mit.edu/gsea). First, a
ranked list was obtained by ranking all genes according
to the correlation between their expression and the
group distinction using the metric signal to noise ratio.
Then the association between a given gene set and the
group was measured by the non-parametric running
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was calculated by walking down the ranked list, increas-
ing when encountering a gene in the given gene set and
decreasing when encountering a gene not in the gene
set. To estimate the statistical significance of the ES, a
nominal p value was calculated by permuting the genes
1,000 times. To adjust for multiple hypothesis testing,
the maximum ES was normalized to account for the
gene set size (NES) and the false discovery rate (FDR)
corresponding to each NES was calculated. The gene
sets used are from Molecular Signatures Database
(MsigDB) [24], catalog C2 functional sets, subcatalog
canonical pathways, which include 639 gene sets from
pathway databases (version 2.5, updated by April, 2008).
These gene sets are canonical representations of a biolo-
gical process compiled by domain experts such as Bio-
Carta, GenMAPP, and KEGG.
Real-time quantitative PCR
Purified total cellular RNA was reverse transcribed using
oligo d(T) and Superscript III followed by RNase H
treatment (Invitrogen Life Technologies). The cDNA
was then subject to real-time quantitative PCR with
defined primers and SYBR Green (Invitrogen Life Tech-
nologies) using Mx3005P™ QPCR System (Stratagene).
The relative quantitation method was used to evaluate
the expression of selected genes with the housekeeping
gene GAPDH as an internal control and the normalizer
for all data.
Additional material
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